Quality of life in scleroderma-related interstitial lung disease and its association with respiratory clinical parameters

Abstract

Objectives:

Interstitial lung disease in systemic sclerosis has a significant impact in the quality of life. This prospective study was designed to determine the correlation between quality of life in systemic sclerosis-interstitial lung disease patients using patient-reported outcome measures and the lung function test parameters, with assessment done at baseline and 1 year.

Methods:

In total, 63 consecutive systemic sclerosis-interstitial lung disease patients underwent lung function test, 6-minute walk distance, and quality of life–validated questionnaires (King’s Brief Interstitial Lung Disease and Functional Assessment of Chronic Illness Therapy dyspnea). King’s Brief Interstitial Lung Disease covers three components, namely chest, breathlessness, and psychological symptoms. The Functional Assessment of Chronic Illness Therapy dyspnea score has Part I (breathlessness symptoms) and Part II (physical limitation due to breathlessness). All assessments except for 6-minute walk distance were done both at baseline and at 12 months.

Results:

Both forced vital capacity predicted percentage at baseline and 12 months had significant negative correlation with the Functional Assessment of Chronic Illness Therapy dyspnea score Part I (p values: 0.038 and <0.001, respectively). Both forced vital capacity and diffuse capacity for carbon monoxide predicted percentage at 12 months were also negatively correlated with Functional Assessment of Chronic Illness Therapy dyspnea score Part II (p values: 0.001 and 0.010, respectively). There was no significant correlation between King’s Brief Interstitial Lung Disease score and the lung function parameters, at both baseline and at 1-year interval. Positive significant correlation was observed between forced vital capacity predicted percentage at baseline and 6-minute walk distance (p = 0.001).

Conclusion:

Systemic sclerosis-interstitial lung disease affects quality of life, which is best assessed using the Functional Assessment of Chronic Illness Therapy dyspnea score as it correlates significantly with the lung function test parameters.

Keywords

Systemic sclerosis interstitial lung disease health-related quality of life patient-reported outcome measures forced vital capacity predicted

Get full access to this article

View all access options for this article.

References

Ingegnoli

Ughi

Mihai

Update on the epidemiology, risk factors, and disease outcomes of systemic sclerosis. Best Pract Res Clin Rheumatol 2018; 32(2): 223–240.

Distler

Highland

Gahlemann

, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380(26): 2518–2528.

Beretta

Santaniello

Lemos

, et al. Validity of the Saint George’s Respiratory Questionnaire in the evaluation of the health-related quality of life in patients with interstitial lung disease secondary to systemic sclerosis. Rheumatology 2007; 46(2): 296–301.

Durheim

Hoffmann-Vold

Eagan

, et al. ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF. BMJ Open Respir Res 2020; 7(1): e000598.

Hinchcliff

Beaumont

Thavarajah

, et al. Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile And Functional Assessment Of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res 2011; 63(11): 1620–1628.

Almeida

Vasconcelos

Quality of life in systemic sclerosis. Autoimmun Rev 2015; 14(12): 1087–1096.

Patel

Siegert

Brignall

, et al. The development and validation of the King’s Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012; 67(9): 804–810.

Van Leeuwen

Ciaffi

Liem

SIE

, et al. Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology 2021; 60(8): 3646–3655.

Fell

Hanekom

Heine

Six-minute walk test protocol variations in low-resource settings—a scoping review. S Afr J Physiother 2021; 77(1): 1549.

10.

Simonneau

Montani

Celermajer

, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53(1): 1801913.

11.

Allanore

Constans

Godard

, et al. Quality of life in SSc-ILD patients: understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. J Scleroderma Relat Disord 2022; 7(1): 49–56.

12.

Khanna

Tashkin

Denton

, et al. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med 2020; 201(6): 650–660.

13.

Lari

Mirfaeizi

Shariati

, et al. The assessment of health-related quality of life in scleroderma-interstitial lung disease. J Cardiothorac Med 2014; 2(2): 152–157.

14.

Swigris

Cutts

Male

, et al. The Living with Pulmonary Fibrosis Questionnaire in progressive fibrosing interstitial lung disease. ERJ Open Res 2021; 7(2): 145.

15.

Hoffmann-Vold

Allanore

Alves

, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 2021; 80(2): 219–227.

16.

Rizzi

Radovanovic

Santus

, et al. Usefulness of six-minute walk test in systemic sclerosis. Clin Exp Rheumatol 2018; 36 Suppl. 113(4): 161–167.

17.

Khanna

Tseng

Farmani

, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63(10): 3078–3085.

18.

Nihtyanova

Schreiber

Ong

, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66(6): 1625–1635.

19.

Lescoat

Huscher

Schoof

, et al. Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region. Rheumatology 2023; 62(6): 2178–2188.

20.

Jaeger

Tikly

, et al. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology 2020; 59(7): 1684–1694.